SCHEMBL4834049

SCHEMBL4834049

Cn1ncc(C=CC(=O)O)c1-c1cccc(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 1/20 0.46
CDK8 P49336 1/20 0.46
PTGS1 P23219 3/20 0.45
MDM2 Q00987 3/20 0.45
LMNA P02545 1/20 0.44
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HTR2A P28223 1/20 0.43
ATM Q13315 1/20 0.42
GRM5 P41594 1/20 0.42
TBXA2R P21731 1/20 0.41
PTGFR P43088 1/20 0.41
PTGER3 P43115 1/20 0.41
PTGER2 P43116 1/20 0.41
PTGIR P43119 1/20 0.41
PTGDR Q13258 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4834032 1.00 CCNC (0.46) CCNCCDK8PTGS1MDM2LMNA
SCHEMBL4829098 0.85 PTGS1 (0.54) CCNCCDK8PTGS1MDM2LMNA
SCHEMBL4829106 0.85 PTGS1 (0.54) CCNCCDK8PTGS1MDM2LMNA
SCHEMBL4831025 0.85 CCNC (0.46) CCNCCDK8PTGS1LMNAALDH1A1
SCHEMBL4831013 0.85 CCNC (0.46) CCNCCDK8PTGS1LMNAALDH1A1
SCHEMBL4826921 0.84 CCNC (0.49) CCNCCDK8PTGS1MDM2LMNA
SCHEMBL4826934 0.84 CCNC (0.49) CCNCCDK8PTGS1MDM2LMNA
SCHEMBL4829235 0.82 PRMT5 (0.44) MDM2LMNAALDH1A1HPGDNPC1
SCHEMBL4833390 0.79 CCNC (0.53) CCNCCDK8PTGS1LMNAALDH1A1
SCHEMBL4833375 0.79 CCNC (0.53) CCNCCDK8PTGS1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed
EP-1556032-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY Takeda Pharmaceutical Company Limited (JP) 2005-07-27 EP disclosed
WO-2004039365-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 CCNC 2548/4885CDK8 2963/4885PTGS1 1761/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 CCNC 2548/4885CDK8 2963/4885PTGS1 1761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.